Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
Hospital for Special Surgery, New York
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
70High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06306157CT.gov Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome | — | Enrolling By Invitation | — | — | — |
NCT04052139CT.gov St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Gabapentin | — | Completed | — | — | — |
NCT03975010CT.gov Buprenorphine Transdermal Patches Pharmacokinetic Study | — | Unknown | — | — | — |
NCT01428583CT.gov Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain | — | Completed | — | — | — |
NCT01595867CT.gov Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo | — | Completed | — | — | — |
NCT01100437CT.gov Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients | — | Terminated | — | — | — |
NCT00420992CT.gov A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee | — | Completed | — | — | — |
NCT00650182CT.gov A Study to Evaluate the Safety of D-TRANS Fentanyl With Naltrexone in Adult Patients With Chronic Pain and Who Are Opioid Tolerant | — | Completed | — | — | — |
NCT01151098CT.gov Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study | — | Completed | — | — | — |
NCT00312195CT.gov Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Pain Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Naltrexone (this asset) | Hospital for Special Surgery, New York | Approved | BB · 71 |
| (±)-Tramadol | EMS | P4 | BBB |
| Lidocaine | National and Kapodistrian University of Athens | P4 | BBB |
| Methadone | Cari Health Inc. | P4 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Stanford University | P4 | BBB |
| Nepenthe | Bursa City Hospital | P4 | BBB |
| Fentanyl | Aga Khan University | P4 | BBB |
| Buprenorphine | Medical University of South Carolina | P4 | BBB |
| Oxycodone | Mayo Clinic | P4 | BBB |
+42 more in the Chronic Pain Syndrome cohort
Other indications for Naltrexone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Alcohol Dependence | — | P4 | BBB · 79 |
| Osteoarthritis | — | P4 | BBB · 75 |
| Rheumatoid Arthritis | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Naltrexone in Chronic Pain Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/naltrexone-chronic-pain-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →